Advertisement

A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial

Published:November 19, 2008DOI:https://doi.org/10.1016/j.ajog.2008.07.062

      Objective

      Results of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial have shown that tamoxifen is associated with a significantly higher incidence of gynecologic adverse events than anastrozole.

      Study Design

      This was a retrospective analysis of all gynecologic adverse events and interventions conducted in patients receiving anastrozole or tamoxifen in the main ATAC trial database.

      Results

      Women taking tamoxifen experienced significantly more gynecologic adverse events than those taking anastrozole (34.2% vs 20.5%; P < .0001) and this led to more diagnostic and/or therapeutic interventions, including an almost 4-fold increase in the number of hysterectomies (5.1% vs 1.3%; P < .0001). The majority of the gynecologic adverse events with tamoxifen occurred during the first 2.5 years.

      Conclusion

      The lower incidence of gynecologic adverse events and interventions with anastrozole and the early occurrence of these events provide further support for using anastrozole as the initial adjuvant treatment for early hormone receptor–positive breast cancer.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bergman L.
        • Beelen M.L.
        • Gallee M.P.
        • Hollema H.
        • Benraadt J.
        • van Leeuwen F.E.
        Risk and prognosis of endometrial cancer after tamoxifen for breast cancer, Comprehensive Cancer Centres' ALERT Group.
        Lancet. 2000; 356: 881-887
        • Cuzick J.
        • Powles T.
        • Veronesi U.
        • et al.
        Overview of the main outcomes in breast-cancer prevention trials.
        Lancet. 2003; 361: 296-300
        • van Leeuwen F.E.
        • Benraadt J.
        • Coebergh J.W.
        • et al.
        Risk of endometrial cancer after tamoxifen treatment of breast cancer.
        Lancet. 1994; 343: 448-452
        • Geisler J.
        • King N.
        • Dowsett M.
        • et al.
        Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
        Br J Cancer. 1996; 74: 1286-1291
        • ATAC Trialists' Group
        Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
        Lancet. 2005; 365: 60-62
        • The ATAC Trialists' Group
        Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
        Lancet. 2002; 359: 2131-2139
        • The Arimidex Tamoxifen Alone or in Combination (ATAC) Trialists' Group
        Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
        Lancet Oncol. 2008; 9: 45-53
        • The ATAC Trialists' Group
        Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses.
        Cancer. 2003; 98: 1802-1810
        • The ATAC Trialists' Group
        Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
        Lancet Oncol. 2006; 7: 633-643
        • Duffy S.
        • Jackson T.L.
        • Lansdown M.
        • et al.
        The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
        Hum Reprod. 2006; 21: 545-553